Novartis finally unloads 300 troubled U.S. generics to India's Aurobindo for $1B
After shopping pieces of its troubled Sandoz business for months, the Swiss drugmaker has unloaded a big chunk-including some easy-to-copy generics and several manufacturing plants to India-based Aurobindo Pharma.